ESC 365 - A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction: the ALTIC-2 study

ESC Premium Access

A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction: the ALTIC-2 study

Session: Poster Session 3 - Antiplatelet therapy

Topic: Antiplatelet Drugs

Speaker: Doctor I. Lianos (London, GB)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Ioannis Lianos

Guy's and St Thomas' NHS Trust Hospitals, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

4 more presentations in this session

Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis

Speaker: Doctor D. Errigo (Turin, IT)

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischaemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients

Speaker: Doctor J. Li (Beijing, CN)

Bleedings during antithrombotic therapy: a blessing in disguise

Speaker: Doctor D. Cosmi (Perugia, IT)

Efficacy and safety of oral anticoagulant versus antiplatelet therapy for secondary prevention of cardiovascular disease in patients without atrial fibrillation

Speaker: Assistant Professor F. Ricci (Chieti, IT)

Access the full session

Poster Session 3 - Antiplatelet therapy

Speakers: Doctor I. Lianos, Doctor D. Errigo, Doctor J. Li, Doctor D. Cosmi, Assistant Professor F. Ricci

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources